The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 10, 2008, Pages 1467-1475

  Kwinta, Przemko ^a   Bik Multanowski, Miroslaw ^a   Mitkowska, Zofia ^a   Tomasik, Tomasz ^a   Pietrzyk, Jacek J ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Genetic predisposition; Soluble VEGF receptor; VLBW infants

Indexed keywords

CYSTEINE; GUANINE; THYMINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ALLELE; ARTICLE; BIRTH WEIGHT; CONTROLLED STUDY; CRYOTHERAPY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETROLENTAL FIBROPLASIA; RISK FACTOR; VERY LOW BIRTH WEIGHT;

BIRTH WEIGHT; CRYOSURGERY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; LASER COAGULATION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RETINOPATHY OF PREMATURITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 51649126694     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0865-9     Document Type: Article

References (32)

1. Haines JL, Fielder A, Baker H, Wilkinson AR (2005) UK population based study of severe retinopathy of prematurity: Screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed 90:240-244
2. Kaiser RS, Trese MT, Williams GA, Cox MS (2001) Adult retinopathy of prematurity: Outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology 108:1647-1653
3. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A (2005) Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 115:e518-e525
4. Tompkins C (2001) A sudden rise in the prevalence of retinopathy of prematurity blindness? Pediatrics 108:526-526
5. Palmer EA (2003) Implications of the Natural Course of Retinopathy of Prematurity. Pediatrics 111:885-886
6. Holmstrom GE, Broberger U, Thomassen P (1998) Neonatal risk factors for retinopathy of prematurity-a population- based study. Acta Ophthalmol Scand 76:204-207
7. Karna P, Muttineni J, Angell L, Karmaus W (2005) Retinopathy of prematurity and risk factors: A prospective cohort study. BMC Pediatr 5:18
8. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM (2002) Retinopathy of prematurity: Recent advances of our understanding. Arch Dis Child Fetal Neonatal Ed 87:F78-F82
9. Schaffer DB, Palmer EA, Plotsky DF, Metz HS, Flynn JT, Tung B, Hardy RJ (1993) Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 100:230-237
10. Hutchinson AK, O'Neil JW, Morgan EN, Cervenak MA, Saunders RA (2003) Retinopathy of prematurity in infants with birth weights greater than 1250 grams. J AAPOS 7:190-194
11. Bizzarro MJ, Hussain N, Jonsson B, Feng R, Ment LR, Gruen JR, Zhang H, Bhandari V (2006) Genetic Susceptibility to Retinopathy of Prematurity. Pediatrics 118:1858-1863
12. Saunders RA, Donahue ML, Christmann LM, Pakalnis AV, Tung B, Hardy RJ, Phelps DL (1997) Racial variation in retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 115:604-608
13. Arnold RW, Kesler K, Avila E (1994) Susceptibility to retinopathy of prematurity in Alaskan Natives. J Pediatr Ophthalmol Strabismus 31:192-194
14. Smith LE (2005) IGF-1 and retinopathy of prematurity in the preterm infant. Biol Neonate 88:237-244
15. Sennlaub F, Chemtob S (2004) VEGFR-1: A safe target for prophylaxis of retinopathy of prematurity? Pediatr Res 55:1-2
16. Shastry BS, Qu X (2007) Lack of association of the VEGF gene promoter (-634 G->C and -460 C->T) polymorphism and the risk of advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:741-743
17. Wei MH, Popescu NC, Lerman MI, Merrill MJ, Zimonjic DB (1996) Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet 97:794-797
18. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443-448
19. Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity - Results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol 121:1684-1696
20. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635-1639
21. Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T, Osaki M, Watanabe M, Nakashima Y, Inukai K, Inoue I, Kawasaki I, Mori K, Yoneya S, Katayama S (2005) Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 333:679-685
22. Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, Sundaresan P (2006) Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 12:336-341
23. Banyasz I, Bokodi G, Vannay A, Szebeni B, Treszl A, Vasarhelyi B, Tulassay T, Szabo A (2006) Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. Curr Eye Res 31:685-690
24. Cooke RW, Drury JA, Mountford R, Clark D (2004) Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci 45:1712-1715
25. Vannay A, Dunai G, Banyasz I, Szabo M, Vamos R, Treszl A, Hajdu J, Tulassay T, Vasarhelyi B (2005) Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res 57:396-398
26. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812-816
27. Kim SH, Choi YM, Choung SH, Jun JK, Kim JG, Moon SY (2005) Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis. Hum Reprod 20:2904-2908
28. Pierce EA, Folez ED, Smith LE (1996) Regulation of Vascular Endothelial Growth Factor by Oxygen in a Model of Retinopathy of Prematurity. Arch Ophthalmol 114:1219-1228
29. Leske DA, Wu J, Mookadam M, Chen Y, Fautsch MP, Holmes JM, Lanier WL (2006) The relationship of retinal VEGF and retinal IGF-1 mRNA with neovascularization in an acidosis-induced model of retinopathy of prematurity. Curr Eye Res 31:163-169
30. Leske DA, Wu J, Fautsch MP, Karger RA, Berdahl JP, Lanier WL, Holmes JM (2004) The role of VEGF and IGF-1 in a hypercarbic oxygen-induced retinopathy rat model of ROP. Mol Vis 10:43-50
31. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS (2004) Variable oxygen and retinal VEGF levels: Correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res 79:623-630
32. Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY (2000) Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: Relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 41:2115-2119